Literature DB >> 10732773

Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs.

D Screnci1, M J McKeage, P Galettis, T W Hambley, B D Palmer, B C Baguley.   

Abstract

Previous work has shown platinum drugs to differ in their effects on the peripheral nervous system. To test whether their differential toxicity was due to differences in their partitioning into the peripheral nervous system, we correlated the hydrophobicity, reactivity, tissue accumulation and neurotoxicity of a series of eight platinum analogues. Neurotoxicity was detected by measuring sensory nerve conduction velocity (SNCV) in Wistar rats treated twice per week at the maximum tolerated dose. Tissue platinum concentrations were measured by inductively coupled plasma mass spectrometry. Hydrophobicity (log P) was measured using an octanol-aqueous shake-flask method. The half-life of platinum drug binding to plasma proteins in vitro was determined. The cumulative dose causing altered SNCV ranged from 15 to > 2050 micromol kg(-1). Ranking of the compounds by their neurotoxic potency in rats (oxaliplatin > R,R-(DACH)PtC4 > ormaplatin > S,S-(DACH)PtCl4 > S,S-(DACH)Pt oxalato > cisplatin > carboplatin > JM216) correlated with the frequency of neurotoxicity in patients (r> 0.99; P < 0.05). Ranking the compounds by their peripheral nerve accumulation was cisplatin > carboplatin > oxaliplatin > R,R-(DACH)PtCl4 = S,S-(DACH)PtCl4 and did not correlate with neurotoxicity. Log P ranged from - 2.53 to -0.16 but did not correlate with neurotoxicity. Log P correlated inversely with platinum accumulation in dorsal root ganglia (r2 = 0.99; P = 0.04), sural nerve (r2 = 0.85; P = 0.025), sciatic nerve (r2 = 0.98; P= 0.0012), spinal cord (r2 = 0.97, P= 0.018) and brain (r2 = 0.98, P= 0.001). Reactivity correlated with neurotoxicity potency in rats (r2 = 0.89, P = 0.0005) and with the frequency of neurotoxicity in patients (r2 = 0.99, P = 0.0002). The hydrophilicity of platinum drugs correlates with platinum sequestration in the peripheral nervous system but not with neurotoxicity. Differences in the reactivity of platinum complexes accounts for some of the variation in their neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10732773      PMCID: PMC2374394          DOI: 10.1054/bjoc.1999.1026

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin.

Authors:  R G van der Hoop; M E van der Burg; W W ten Bokkel Huinink; C van Houwelingen; J P Neijt
Journal:  Cancer       Date:  1990-10-15       Impact factor: 6.860

2.  Protein binding of five platinum compounds. Comparison of two ultrafiltration systems.

Authors:  W J van der Vijgh; I Klein
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 3.  Determination of hydrophobic parameters by reversed-phase liquid chromatography: theory, experimental techniques, and application in studies on quantitative structure-activity relationships.

Authors:  T Braumann
Journal:  J Chromatogr       Date:  1986-11-14

4.  Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity.

Authors:  R W Gregg; J M Molepo; V J Monpetit; N Z Mikael; D Redmond; M Gadia; D J Stewart
Journal:  J Clin Oncol       Date:  1992-05       Impact factor: 44.544

Review 5.  Testicular cancer: an oncological success story.

Authors:  E H Einhorn
Journal:  Clin Cancer Res       Date:  1997-12       Impact factor: 12.531

6.  Lack of neurotoxicity of oral bisacetatoamminedichlorocyclohexylamine-platinum(IV) in comparison to cisplatin and tetraplatin in the rat.

Authors:  M J McKeage; F E Boxall; M Jones; K R Harrap
Journal:  Cancer Res       Date:  1994-02-01       Impact factor: 12.701

7.  Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.

Authors:  R J Schilder; F P LaCreta; R P Perez; S W Johnson; J M Brennan; A Rogatko; S Nash; C McAleer; T C Hamilton; D Roby
Journal:  Cancer Res       Date:  1994-02-01       Impact factor: 12.701

8.  Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies.

Authors:  S W Thompson; L E Davis; M Kornfeld; R D Hilgers; J C Standefer
Journal:  Cancer       Date:  1984-10-01       Impact factor: 6.860

9.  Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812).

Authors:  T J O'Rourke; G R Weiss; P New; H A Burris; G Rodriguez; J Eckhardt; J Hardy; J G Kuhn; S Fields; G M Clark
Journal:  Anticancer Drugs       Date:  1994-10       Impact factor: 2.248

Review 10.  Comparative adverse effect profiles of platinum drugs.

Authors:  M J McKeage
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

View more
  38 in total

1.  Molecular and statistical modeling of reduction peak potential and lipophilicity of platinum(IV) complexes.

Authors:  James A Platts; Giuseppe Ermondi; Giulia Caron; Mauro Ravera; Elisabetta Gabano; Luca Gaviglio; Giorgio Pelosi; Domenico Osella
Journal:  J Biol Inorg Chem       Date:  2010-11-16       Impact factor: 3.358

2.  DFT-based QSAR and QSPR models of several cis-platinum complexes: solvent effect.

Authors:  Pubalee Sarmah; Ramesh C Deka
Journal:  J Comput Aided Mol Des       Date:  2009-03-24       Impact factor: 3.686

Review 3.  Uptake carriers and oncology drug safety.

Authors:  Jason A Sprowl; Alex Sparreboom
Journal:  Drug Metab Dispos       Date:  2013-12-30       Impact factor: 3.922

4.  [Analgesic effect of dexmedetomidine on oxaliplatin-induced neuropathic pain in rats].

Authors:  Shuangfeng Li; Bishan Ouyang; Xin Zhao; Yaping Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-07-30

5.  Platinum compounds for high-resolution in vivo cancer imaging.

Authors:  Miles A Miller; Bjorn Askevold; Katherine S Yang; Rainer H Kohler; Ralph Weissleder
Journal:  ChemMedChem       Date:  2014-02-06       Impact factor: 3.466

Review 6.  [Painful hyperexcitability syndrome with oxaliplatin containing chemotherapy. Clinical features, pathophysiology and therapeutic options].

Authors:  T Kowalski; C Maier; A Reinacher-Schick; U Schlegel
Journal:  Schmerz       Date:  2008-02       Impact factor: 1.107

7.  Differential expression of ATP7A, ATP7B and CTR1 in adult rat dorsal root ganglion tissue.

Authors:  Virginia Ip; Johnson J Liu; Julian F B Mercer; Mark J McKeage
Journal:  Mol Pain       Date:  2010-09-13       Impact factor: 3.395

8.  Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.

Authors:  Andrew Hill; Peter Bergin; Fritha Hanning; Paul Thompson; Michael Findlay; Dragan Damianovich; Mark J McKeage
Journal:  BMC Cancer       Date:  2010-08-23       Impact factor: 4.430

9.  Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity.

Authors:  S M F Jamieson; J Liu; T Hsu; B C Baguley; M J McKeage
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

10.  Oxaliplatin-induced loss of phosphorylated heavy neurofilament subunit neuronal immunoreactivity in rat DRG tissue.

Authors:  Stephen M F Jamieson; Joshuan Subramaniam; Johnson J Liu; Nancy N Jong; Virginia Ip; Bronwen Connor; Mark J McKeage
Journal:  Mol Pain       Date:  2009-11-18       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.